Table 3.
Larger studies of suicide gene modified donor lymphocyte infusion.
| Graft | Disease | Suicide | Relapse N | N (aGVHD; | N (cGVHD; | N, Clinical | References |
|---|---|---|---|---|---|---|---|
| status (N) | gene (N) | response) | response) | response | |||
| TCD-Haplo | CR (9) AD (1) | iCasp9 (10) | 4 | 4 (CR) | 0 | 5 CCR | Di Stasi et al., 2011; Zhou et al., 2014 |
| N/A | Relapse or EBV-PTLD (8) | HSV-TK (8) | N/A | 2 (CR) | 1(PR) | 3 CR, 2 PR | Bonini et al., 1997 |
| TCD-MRD | AD (5) CR (3) CP (4) | HSV-TK (12) | 2 | 5; CR 3/5 | 1 (CR) | 4 (CR/CCR) | Tiberghien et al., 2001 |
| MRD, MMRD | Relapse (30) | HSV-TK (23) | N/A | 4 (CR) | 1 (clinical benefit) | 6 CR, 5 PR | Ciceri et al., 2007 |
| TCD-Haplo | AD (20) CR (30) | HSV-TK (28) | 17 | 10 (CR) | 1(CR) | 5 CR, 11 CCR | Ciceri et al., 2009 |
Legend: GVHD, graft-versus-host-disease; a, acute; c, chronic; N, number; TCD, T cell depleted; haplo, 5/10 HLA matched haploidentical; (C)CR, (continuous) complete remission; AD, active disease; iCasp9, inducible Caspase9; D, day(s); EBV-PTLD, Epstein-Barr virus post-transplant lymphoproliferative disease; HSV-TK, herpes simplex virus thymidine kinase; NA, not available/applicable; PR, partial response; (M)MRD, (mis)matched related donor; CP, chronic phase.